Syneos Health (SYNH) Stock

Syneos Health (SYNH) announces an expanded collaboration with Oracle to accelerate patient recruitment capabilities.

Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Syneos Health (SYNH) partners with uMotif to deliver the patient-centric eClinical platform.

Syneos Health's (SYNH) purchase price represents a 24% premium to its unaffected closing stock price prior to the announcement. Margin pressure continues to weigh on the stock.

Syneos Health (SYNH) is set to become private company following a $7.1 billion merger deal to be acquired by a private investment consortium.

Syneos Health (SYNH) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.67 per share. This compares to earnings of $1.01 per share a year ago.

Syneos Health (NASDAQ: SYNH ) stock is on the rise Wednesday as investors react to news of a $7.1 billion acquisition deal. A group of investors led by Elliott Investment Management intend to take the healthcare company private for a price of $43 per share.

The sale of Syneos Health comes as the company faces muted spending from drug developers for its clinical-research services.

Syneos Health Inc.'s SYNH stock surged 19% in extended trading Tuesday on a Bloomberg report that a consortium of Elliott Investment Management, Patient Square Capital and Veritas Capital is in advanced talks to acquire Syneos, a drug-research services company. A deal could be announced as soon as this week, according to people with knowledge of the talks, the report said.